Simple human pharmacokinetic models scaled‐up using cytochrome P450 3A‐dependent 6β‐hydroxycortisol data from humanized‐liver mice can account for monitoring of cortisol administered orally to treat adrenal insufficiency
British Journal of Clinical Pharmacology · 15.11.2026
DOI: 10.1002/bcp.70919 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 15.11.2026. Verfasst von Hiroshi Yamazaki und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo, Japan. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aim
Endogenous cortisol, a stress biomarker, is used as a cytochrome P450 3A‐dependent biomarker for human phenotyping. Because adrenal hypofunction is characterized by low endogenous plasma cortisol levels, exogenous cortisol is therapeutically administered orally in two or three divided daily doses. Simple pharmacokinetic models were established for cortisol monitoring following oral administration.
Methods
One set of model input parameters was based on reported plasma cortisol values in two male Japanese volunteers (designated A and B) orally administered deuterium‐labelled cortisol. Simple physiologically based pharmacokinetic (PBPK) models were also extrapolated from humanized‐liver mice data and used to predict human steady‐state plasma concentrations of cortisol and its 6β‐hydroxylated metabolite.
Results
Four groups of humanized‐liver mice were used, each with a different human donor. The cortisol clearance values varied by a factor of two across the four groups. This variability was reflected in the in silico clearance values generated as input parameters for PBPK models. Virtual human area‐under‐the‐curve values after oral cortisol (18 mg/day total for 1 week) administered as divided doses once, twice, or thrice daily were used to calculate the mean cortisol and 6β‐hydroxycortisol concentrations. For Human A, the mean cortisol level was double that of Human B under the present simulations.
Conclusions
When using 6β‐hydroxycortisol as an endogenous biomarker for clinical treatment with exogenous agents, the dosage and timing of oral cortisol should be determined considering individual variations, such as body weight and the twofold variability in baseline normal metabolic enzyme activity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo, Japan.
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Yamazaki, H., & Shimizu, M. (2026). Simple human pharmacokinetic models scaled‐up using cytochrome P450 3A‐dependent 6β‐hydroxycortisol data from humanized‐liver mice can account for monitoring of cortisol administered orally to treat adrenal insufficiency. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70919
Vancouver
Yamazaki H, Shimizu M. Simple human pharmacokinetic models scaled‐up using cytochrome P450 3A‐dependent 6β‐hydroxycortisol data from humanized‐liver mice can account for monitoring of cortisol administered orally to treat adrenal insufficiency. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70919
BibTeX
@article{Yamazaki2026,
author = {Yamazaki, Hiroshi and Shimizu, Makiko},
title = {Simple human pharmacokinetic models scaled‐up using cytochrome P450 3A‐dependent 6β‐hydroxycortisol data from humanized‐liver mice can account for monitoring of cortisol administered orally to treat adrenal insufficiency},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70919}
}
EUVIMED